Compare VICI & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VICI | WAT |
|---|---|---|
| Founded | 2016 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Laboratory Analytical Instruments |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7B | 33.5B |
| IPO Year | 2017 | 1996 |
| Metric | VICI | WAT |
|---|---|---|
| Price | $27.88 | $366.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | $33.75 | ★ $379.19 |
| AVG Volume (30 Days) | ★ 5.6M | 965.3K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 6.29% | N/A |
| EPS Growth | ★ 1.95 | 0.47 |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $4,006,116,000.00 | N/A |
| Revenue This Year | $4.47 | $104.66 |
| Revenue Next Year | $1.67 | $10.40 |
| P/E Ratio | $33.12 | ★ N/A |
| Revenue Growth | ★ 4.08 | N/A |
| 52 Week Low | $26.55 | $275.05 |
| 52 Week High | $34.01 | $414.15 |
| Indicator | VICI | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 46.13 | 58.34 |
| Support Level | $27.45 | $285.81 |
| Resistance Level | $28.79 | $364.99 |
| Average True Range (ATR) | 0.48 | 11.90 |
| MACD | -0.10 | 1.88 |
| Stochastic Oscillator | 47.14 | 66.06 |
VICI Properties Inc is a real estate investment trust based in the United States. It engaged in the business of owning and acquiring gaming, hospitality, wellness, entertainment and leisure destinations, subject to long-term triple net leases. It own nearly 93 experiential assets across a geographically portfolio consisting of nearly 54 gaming properties and nearly 39 other experiential properties across the United States and Canada, including Caesars Palace Las Vegas, MGM Grand and the Venetian Resort Las Vegas.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with BD's life science and diagnostics business, which increased its concentration in diagnostics (versus none now) and discovery-related life science tools.